資源 » 參考數(shù)據(jù)庫(kù) » 客戶發(fā)表文獻(xiàn)

至今，GenScript的服務(wù)及產(chǎn)品已被Cell, Nature, Science, PNAS等1300多家生物醫(yī)藥類雜志引用近萬(wàn)次，處于行業(yè)領(lǐng)先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學(xué)等約400家全球著名機(jī)構(gòu)使用GenScript的基因合成、多肽服務(wù)、抗體服務(wù)和蛋白服務(wù)等成功地發(fā)表科研成果，再次證明GenScript 有能力幫助業(yè)內(nèi)科學(xué)家Make research easy.

KIR2DS5 allotypes that recognize the C2 epitope of HLA‐C are common among Africans and absent from Europeans

Original Research. 2018;

Jeroen H. Blokhuis , Hugo G. Hilton , Lisbeth A. Guethlein , Paul J. Norman , Neda Nemat-Gorgani , Annettee Nakimuli , Olympe Chazara , Ashley Moffett , & Peter Parham

Products/Services Used	Details	Operation
Recombinant Proteins	Introduction: KIR2DS5 is an activating human NK cell receptor of lineage III KIR. These include both inhibitory KIR2DL1, 2 and 3 and activating KIR2DS1 that recognize either the C1 or C2 epitope of HLA-C. In Europeans KIR2DS5 is essentially monomorphic, with KIR2DS5002 being predominant. Pioneering investigations showed that KIR2DS5002 has activating potential, but cannot recognize HLA-A, -B, or -C. Subsequent studies have shown that KIR2DS5 is highly polymorphic in Africans, and that KIR2DS5006 protects pregnant Ugandan women from preeclampsia. Because inhibitory C2-specific KIR2DL1 correlates with preeclampsia, whereas activating C2-specific KIR2DS1 protects, this association pointed to KIR2DS5006 being an activating C2-specific receptor. To test this hypothesis we made KIR-Fc fusion proteins from all ten KIR2DS5 allotypes and tested their binding to a representative set of HLA-A, -B and -C allotypes. Results: Six African-specific KIR2DS5 bound to C2+ HLA-C but not to other HLA class I. Their avidity for C2 is 20% that of C2-specific KIR2DL1 and 40% that of C2-specific KIR2DS1. Among the African C2 receptors is KIR2DS5006, which protected a cohort of pregnant Ugandans from pre-eclampsia. Three African KIR2DS5 allotypes and KIR2DS5002, bound no HLA-A, -B or -C. As a group the C2-binding KIR2DS5 allotypes protect against pre-eclampsia compared to the nonbinding KIR2DS5 allotypes. Natural substitutions that contribute to loss or reduction of C2 receptor function are at positions 127, 158, and 176 in the D2 domain. Conclusions: KIR2DS5005 has the KIR2DS5 consensus sequence, is the only allele found at both centromeric and telomeric locations of KIR2DS5, and is likely the common ancestor of all KIR2DS5 alleles. That KIR2DS5005 has C2 receptor activity, points to KIR2DS5002, and other allotypes lacking C2 receptor function, being products of attenuation, a characteristic feature of most KIR B haplotype genes. Alleles encoding attenuated and active KIR2DS5 are present in both centromeric and telomeric locations. A sequence encoding residues 1–224 of the mature KIR2DS5005 protein was synthesized by Genscript...	Get A Quote
Bacterial Expression System		Get A Quote

摘要

Introduction: KIR2DS5 is an activating human NK cell receptor of lineage III KIR. These include both inhibitory KIR2DL1, 2 and 3 and activating KIR2DS1 that recognize either the C1 or C2 epitope of HLA-C. In Europeans KIR2DS5 is essentially monomorphic, with KIR2DS5002 being predominant. Pioneering investigations showed that KIR2DS5002 has activating potential, but cannot recognize HLA-A, -B, or -C. Subsequent studies have shown that KIR2DS5 is highly polymorphic in Africans, and that KIR2DS5006 protects pregnant Ugandan women from preeclampsia. Because inhibitory C2-specific KIR2DL1 correlates with preeclampsia, whereas activating C2-specific KIR2DS1 protects, this association pointed to KIR2DS5006 being an activating C2-specific receptor. To test this hypothesis we made KIR-Fc fusion proteins from all ten KIR2DS5 allotypes and tested their binding to a representative set of HLA-A, -B and -C allotypes. Results: Six African-specific KIR2DS5 bound to C2+ HLA-C but not to other HLA class I. Their avidity for C2 is 20% that of C2-specific KIR2DL1 and 40% that of C2-specific KIR2DS1. Among the African C2 receptors is KIR2DS5006, which protected a cohort of pregnant Ugandans from pre-eclampsia. Three African KIR2DS5 allotypes and KIR2DS5002, bound no HLA-A, -B or -C. As a group the C2-binding KIR2DS5 allotypes protect against pre-eclampsia compared to the nonbinding KIR2DS5 allotypes. Natural substitutions that contribute to loss or reduction of C2 receptor function are at positions 127, 158, and 176 in the D2 domain. Conclusions: KIR2DS5005 has the KIR2DS5 consensus sequence, is the only allele found at both centromeric and telomeric locations of KIR2DS5, and is likely the common ancestor of all KIR2DS5 alleles. That KIR2DS5005 has C2 receptor activity, points to KIR2DS5002, and other allotypes lacking C2 receptor function, being products of attenuation, a characteristic feature of most KIR B haplotype genes. Alleles encoding attenuated and active KIR2DS5 are present in both centromeric and telomeric locations. Introduct